SNORD90 induces glutamatergic signaling following treatment with monoaminergic antidepressants
Rixing Lin,Aron Kos,Juan Pablo Lopez,Julien Dine,Laura M Fiori,Jennie Yang,Yair Ben-Efraim,Zahia Aouabed,Pascal Ibrahim,Haruka Mitsuhashi,Tak Pan Wong,El Cherif Ibrahim,Catherine Belzung,Pierre Blier,Faranak Farzan,Benicio N Frey,Raymond W Lam,Roumen Milev,Daniel J Muller,Sagar V Parikh,Claudio Soares,Rudolf Uher,Corina Nagy,Naguib Mechawar,Jane A Foster,Sidney H Kennedy,Alon Chen,Gustavo Turecki,The Canadian Biomarker Integration Network in Depression (CAN-BIND)
DOI: https://doi.org/10.1101/2023.01.31.23285298
2023-02-04
MedRxiv
Abstract:Most available antidepressants target the serotonergic system, selectively or non-selectively, and yield slow and inconsistent clinical responses, whereas the monoamine changes they elicit do not correlate with treatment response. Recent findings point to the glutamatergic system as a target for rapid acting antidepressants. Investigating different cohorts of depressed individuals treated with serotonergic and other monoaminergic antidepressants, we found that the expression of a small nucleolar RNA, SNORD90, was elevated following treatment response. When we increased SNORD90 levels in the mouse anterior cingulate cortex (ACC), a brain region regulating mood responses, we observed antidepressive-like behaviors. We identified neuregulin 3 (NRG3) as one of the targets of SNORD90, which we show is regulated through the accumulation of N6-methyladenosine modifications leading to YTHDF2 mediated RNA decay. We further demonstrate that a decrease in NRG3 expression resulted in increased glutamatergic release in the mouse ACC. These findings support a molecular link between monoaminergic antidepressant treatment and glutamatergic neurotransmission.